Livzon Pharma boosts transactions with MAB subsidiary amid expansion

Livzon Pharmaceutical Group Inc. announced its board approved adjustments to the annual caps for continuing connected transactions with Livzon MAB, a connected subsidiary. On December 5, 2025, the annual cap for utility provisions was increased from RMB11.80 million to RMB16.00 million for the period from January 1, 2025, to December 31, 2025. This increase is primarily attributed to Livzon MAB's expanded operational scale and higher energy consumption from production, drug R&D (including the LZSN2401 project), and daily office operations.

Concurrently, the annual cap for the group's provision of drug contract R&D and manufacturing services to Livzon MAB for the same period was raised from RMB11.60 million to RMB45.00 million. This significant increase is driven by expanded R&D services for projects like LZM012, B-01, and LZSN2401, and higher demand for manufacturing services due to increased sales of Livzon MAB's Human Chorionic Gonadotropin (HCG) product. These supplemental agreements form an integral part of the existing 2025 Utilities Framework Agreement and 2025 Service Framework Agreement.

These transactions are subject to reporting and announcement requirements but are exempt from independent shareholders' approval under Chapter 14A of the Hong Kong Listing Rules. The company's directors consider the terms of these agreements fair, reasonable, and in the best interests of the company and its shareholders.